JonesResearch downgraded Editas Medicine (EDIT) to Hold from Buy with no price target after the company announced their decision to end the development of reni-cel, an ex vivo gene editor for the treatments of Sickle Cell Disease and Beta-Thalassemia. The firm, which notes that the company expects human proof of concept data from its in vivo gene editing technology in approximately two years, is downgrading as it continues to watch for additional in vivo editing data in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Salesforce upgraded, ServiceNow downgraded: Wall Street’s top analyst calls
- Editas Medicine price target lowered to $4 from $5 at RBC Capital
- Editas Medicine downgraded to Neutral from Buy at Chardan
- Editas Medicine price target lowered to $8 from $10 at Baird
- Editas Medicine price target lowered to $3 from $5 at Barclays